Business Wire

NEUSTAR

14.1.2020 09:02:07 CET | Business Wire | Press release

Share
Neustar Delivers UltraThreat Feeds for More Effective Data Security

Neustar® , Inc., a global information services company and leader in identity resolution, today announced the release of UltraThreat Feeds, a new service that provides its enterprise customers with access to real-time threat data to help them better identify cyber threats as they evolve. Designed by Neustar’s renowned security experts and leading academic researchers, the service – unique to Neustar – enables security and threat intelligence teams of all sizes to access threat feeds based on analysis and observations curated from Neustar’s expansive DNS, OneID and IP decisioning data.

Incorporating proprietary data derived from Neustar’s Security Portfolio & OneID identity resolution platform, UltraThreat Feeds can be ingested into a client’s existing platform to deliver superior threat data and provide valuable insights to unique and developing threats in near real-time.

“With the average cost of a data breach now at nearly $4 million, enterprises are investing significant resources into threat intelligence solutions to better defend themselves. A key change is enabling network and application security tools with improved real-time awareness of active threats,” said Rodney Joffe, security CTO, senior technologist and fellow at Neustar. “For example, SIEMs, TIPs, Next Gen Firewalls, IPS/IDS, WAFs, and DNS Firewalls all require threat data to power their security functions to detect and block malicious actors. Neustar’s UltraThreat Feeds service delivers deep, rich threat data, giving users the power to identify indicators of compromise or malicious activity in near real time and act accordingly to limit or even prevent attacks.”

UltraThreat Feeds enable Neustar customers to identify:

  • Malicious Domain Generation Algorithms (“DGAs”) – When malicious actors register one of the thousands of domains that are created by the DGAs within their malware, and that then allow the actors to control infected hosts from their Command and Control Servers (C2).
  • Suspicious DNS Tunneling Attempts – When Domains leverage the DNS protocol to create a “tunnel” to exfiltrate data past customers’ security measures.
  • Newly Observed Domains – When a Domain with little or no history is suddenly active, which presents increased risk.
  • Domain Updates (Nameserver or Hosting IP Address) – When there are indications that a domain has been hijacked.
  • Domain Spoofing (Business Email Compromise) – When fake online personas trick victims into making fraudulent transactions by imitating or resembling legitimate domains.

Neustar’s UltraThreat Feeds service has an advantage over competitors, thanks to the availability of its own unique data assets, including DNS data exhaust collected from the more than 100 billion queries received from 30 globally distributed nodes every day and supplemented by the IP address intelligence and analytics processed across Neustar’s product suite. Combined with behavioural analysis and pattern-based research, this advantage enables Neustar to derive truly unique insights into malicious activity. With insight gained from Neustar’s globally distributed authoritative and recursive DNS network, Neustar OneID, IP Intelligence geolocation and risk data, UltraThreat Feeds can provide a proprietary view of global threats to help identify and stop bad traffic, both inbound and outbound.

"With increasing attacker sophistication, and renewed aggression from nation-state adversaries focused on corporate espionage, many organisations are trying to find out how to properly leverage these [threat intelligence] services to protect themselves," wrote Forrester analysts Josh Zelonis and Joseph Blankenship in the report, The Forrester Tech Tide™: Zero Trust Threat Detection And Response, Q1 2019.

For more technical details on Neustar UltraThreat Feeds, visit https://www.home.neustar/security-intelligence/ultra-threat-detection-feeds .

-ENDS-

About Neustar

Neustar is an information services and technology company and a leader in identity resolution providing the data and technology that enables trusted connections between companies and people at the moments that matter most. Neustar offers industry-leading solutions in Marketing, Risk, Communications, Security and Registry that responsibly connect data on people, devices and locations, continuously corroborated through billions of transactions. Neustar serves more than 8,000 clients worldwide, including 60 of the Fortune 100. Learn how your company can benefit from the power of trusted connections here: www.home.neustar .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release

Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye